Organisation paid for research Program year 2025 Source: CMS Open Payments

PMG Research of Wilmington

Neither a doctor nor a teaching hospital

Research payments

$1,062,046

641 payments

Through program year 2025, PMG Research of Wilmington is reported as receiving $1,062,046 in research payments, across 641 payments.

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$4,621	11
2024	Research	$9,493	4
2023	Research	$35,348	10
2022	Research	$36,492	29
2021	Research	$98,843	209
2020	Research	$481,768	180
2019	Research	$395,482	198

Breakdown

Who paid Research payments · program years 2019–2025

Merck Sharp & Dohme Corporation $390,229 159 payments
Becton, Dickinson and Company $196,545 9 payments
Boehringer Ingelheim Pharmaceuticals, Inc. $107,615 30 payments
AstraZeneca Pharmaceuticals LP $78,857 23 payments
Ironwood Pharmaceuticals, Inc $50,219 8 payments
American Regent $40,160 8 payments
AstraZeneca UK Limited $39,778 14 payments
Boehringer Ingelheim Canada Ltd.Ltee $30,145 52 payments
Sanofi US Services Inc. $24,324 6 payments
Flexion Therapeutics, Inc. $21,823 2 payments

Studies the money was for Research payments · program years 2019–2025

Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age $327,841 30 payments
Veritor Antigen Assay $196,545 9 payments
DCRI Registry Study $80,658 11 payments
McP-103-205 $50,219 8 payments
Heart_FID $40,160 8 payments
A Long Term Outcomes Study to Assess STatin Residual Risk Reduction with EpaNova in HiGh Cardiovascular Risk PatienTs with Hypertriglyceridemia $36,601 20 payments
BI 767551 (EX14870) Ph II/III SARS-COV-2 Ambulatory Pts IV $30,145 52 payments
A Phase 3b Randomized Double-blind, Placebo Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Gefapixant in Women with Chronic Cough and Stress Urinary Incontinence $30,122 7 payments
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age $28,702 108 payments
A Multinational Randomised Double Blind Placebo Controlled Trial to Evaluate the Effect of Ticagrelor 90 mg twice daily on the Incidence of Cardiovascular Death Myocardial Infarction or Stroke in Patients with Type 2 Diabetes $23,233 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.